For research use only. Not for therapeutic Use.
Phacolysine (Cat.No:I014568) is a pharmaceutical compound used in the treatment of cataracts. It belongs to the class of antiglaucoma agents and works by reducing the production of aqueous humor in the eye. Phacolysine helps to relieve intraocular pressure and can be administered orally or topically in eye drops for therapeutic purposes.
| Catalog Number | I014568 |
| CAS Number | 3863-80-7 |
| Synonyms | Phacolysine; Quinax; Azapentacene; Jing Ming;;sodium 5,12-dihydroquinoxalino[2,3-b]phenazine-2,9-disulfonate |
| Molecular Formula | C18H10N4Na2O6S2 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| InChI | InChI=1S/C18H12N4O6S2.2Na/c23-29(24,25)9-1-3-11-13(5-9)21-17-8-16-18(7-15(17)19-11)22-14-6-10(30(26,27)28)2-4-12(14)20-16;;/h1-8,19-20H,(H,23,24,25)(H,26,27,28);;/q;2*+1/p-2 |
| InChIKey | XLNKBYYWZULHIR-UHFFFAOYSA-L |
| SMILES | [O-]S(c1cc(N=c2c(N3)cc4c(Nc5c(N=4)cc(S([O-])(=O)=O)cc5)c2)c3cc1)(=O)=O.[Na+].[Na+] |
| Reference | </br>1: Yu X, Liao Z, Yao Q, Liu H, Xie W. Spectroscopic studies on the interaction of Phacolysin and bovine serum albumin. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Jun 5;127:231-6. doi: 10.1016/j.saa.2014.02.064. Epub 2014 Feb 27. PubMed PMID: 24632176.</br>2: Shvachko AG, Formaziuk VE, Sergienko VI. [Chemiluminescence decrease of singlet oxygen in NaClO+H2O2 reaction in the presence of different anti-cataract drugs]. Biull Eksp Biol Med. 1991 Jul;112(7):42-4. Russian. PubMed PMID: 1793850.</br>3: Maĭchuk IuF, Bazukina LP, Orlovskaia LE, Lapshina NA, Khaitova KN, Iakushina LN. [Use of phacolin in patients with allergic reaction to anti-cataract eye drops]. Vestn Oftalmol. 1991 May-Jun;107(3):68-71. Russian. PubMed PMID: 1755171.</br>4: Svachko AG, Formaziuk VE, Sergienko VI. [Decrease of singlet oxygen chemiluminescence by the presence of carnosine]. Biull Eksp Biol Med. 1990 Aug;110(8):155-7. Russian. PubMed PMID: 2291961.</br>5: Stankiewicz A, Poppe E, Stasiewicz B, Gołebiowska-Hrycukowa A. [Evaluation of the effectiveness of Quinax in the prevention of the development of senile cataract]. Klin Oczna. 1990 Aug;92(3-4):52-4. Polish. PubMed PMID: 2263035.</br>6: Chasovnikova LV, Formazyuk VE, Sergienko VI, Boldyrev AA, Severin SE. The antioxidative properties of carnosine and other drugs. Biochem Int. 1990;20(6):1097-103. PubMed PMID: 2369412.</br>7: Popa DP, Vasinca D. [Treatment of cataract with Quinax]. Rev Chir Oncol Radiol O R L Oftalmol Stomatol Ser Oftalmol. 1988 Oct-Dec;32(4):273-8. Romanian. PubMed PMID: 2978086.</br>8: Mal’tsev EV. [Conservative treatment of cataract]. Oftalmol Zh. 1984;(7):430-4. Review. Russian. PubMed PMID: 6396559.</br>9: Zygulska-Mach H, Pioruńska M, Paziewski E. [Use of the preparation quinax in the trial treatment of senile and secondary cataract]. Wiad Lek. 1982 Nov 1;35(19-20):1239-43. Polish. PubMed PMID: 6761971.</br>10: Prost M, Toczołowski J. [Clinical evaluation of the inhibitory effect of Quinax on the progression of senile cataract]. Klin Oczna. 1982 Mar;84(3):71-2. Polish. PubMed PMID: 6757553.</br>11: Eyada KA. Metabolism of cataract and medical treatment. Metab Pediatr Ophthalmol. 1981;5(2):99-103. PubMed PMID: 7289691.</br>12: Fukushi S, Suzuki T. [Studies on azapentacene, anti-cataract agent (author’s transl)]. Nippon Ganka Gakkai Zasshi. 1981 Jan;85(1):37-43. Japanese. PubMed PMID: 7258001.</br>13: Jabłoński J, Pankowska B. [Quinax preparation in conservative treatment of senile cataract (author’s transl)]. Klin Oczna. 1980 Apr;82(4):219-20. Polish. PubMed PMID: 7431800.</br>14: FUJIYAMA H, SAKAI C, TANAKA N, NARA N, FUTAGAMI S, ADACHI H. [Treatment of cataracta congenita, traumatica and complicata with the eye-lotion ‘Phacolin’]. Rinsho Ganka. 1962 Apr;16:389-93. Japanese. PubMed PMID: 13895779. </br> </br> |
